drugset / Trial / NCT02506023

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023

Phase 1 Completed 2 enrolled Emory University
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).

Timeline

Start
2015-07
Primary completion
2018-06-15
Completion
2018-06-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desmopressin Peptide 0.3 ug/kg Intravenous

Indications